Portrazza

Chemical Namenecitumumab
Dosage FormInjection (intravenous; 800 mg/50 mL)
Drug ClassMonoclonal antibodies
SystemRespiratory
CompanyEli Lilly and Company
Approval Year2015

Indication

  • In combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic squamous non-small cell lung cancer.
Last updated on 10/15/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Portrazza (necitumumab) Prescribing Information2015Lilly USA, LLC, Indianapolis, IN